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ABSTRACT 
Cross-system comparisons of drug delivery vectors are essential to ensure optimal design. An in-
vitro experimental protocol is presented that separates the role of the delivery vector from that of its 
cargo in determining the cell response, thus allowing quantitative comparison of different systems. 
The technique is validated through benchmarking of the dose-response of human fibroblast cells 
exposed to the cationic molecule, polyethylene imine (PEI); delivered as a free molecule and as a 
cargo on the surface of CdSe nanoparticles and Silica microparticles. The exposure metrics are 
converted to a delivered dose with the transport properties of the different scale systems 
characterized by a delivery time, . The benchmarking highlights an agglomeration of the free PEI 
molecules into micron sized clusters and identifies the metric determining cell death as the total 
number of PEI molecules presented to cells, determined by the delivery vector dose and the surface 
density of the cargo. 
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1. Background 
A drug molecule or imaging payload must reach its intended site of action to exert an efficient 
therapeutic or diagnostic action and to prevent adverse side effects.[1,2] The delivery of active 
agents to the target organ or disease loci generally requires negotiation of numerous bio-barriers 
mainly comprised of cells from different origins.[3–5] Consequently, there has been a rapid 
development in novel nano and micro-scale vectors to more efficiently deliver drugs, genetic 
material, and imaging contrast agents to their target locations.[6–8] While particulates can be 
administered locally or systemically through various routes (e.g. dermal, intravenous, oral, 
pulmonary), their initial performance evaluation includes in vitro studies in cell cultures.  
In this work, we use the “on contact” toxicity of PEI as a probe of the dynamics of arrival to the cell 
surface of the same material in carriers of different sizes. In general, this assessment is very 
important as the dynamic of arrival can further be translated to multiple biological outputs (toxicity 
being one of them). It is becoming increasingly evident that nano and micro materials cannot be 
treated in the same manner as chemical compounds with regards to their safety and efficacy 
assessment [9], as their unique physicochemical properties are responsible for unexpected 
interactions with experimental and biological systems [10,11]. Despite the wide use of in vitro 
systems for biological assessment of NPs, the direct measure of cellular dosimetry has largely been 
overlooked in favour of using overall metrics of exposure, principally particle concentration on a 
mass [12], number, or surface area basis. This is due to the difficulties in measuring particle arrival 
at the cell interface. In this context, below we discuss various tests for evaluation of biological 
(toxicity/efficacy) responses as well the effects of particles of different sizes on the above.  
In general, there is an urgent need in toxicity tests or dose response assays to de-couple the physical 
effects acting upon a particle from their biological effects so that true biological response to 
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variables such as particle size or shape can be determined. This is particularly important in 
investigations which are directly comparing cellular responses across multiple materials or 
materials of different sizes [13–15]. However, physical effects in a system are commonly ignored 
and the cellular response observed is thought to be solely biology-driven, which may generally lead 
to misinterpretation of the obtained results. For instance, cytotoxicity assays investigating the role 
of cell cycle in cellular uptake and toxicity do not take into account the non-linear delivery rate of 
nano and micro-particles and consider responses to be uniquely driven by biological changes in the 
cell during proliferation [16]. In terms of the efficacy, the rate of arrival of an agent to the cell 
surface is extremely important when comparing therapeutic entities such as low molecular weight 
drugs, proteins and oligonucleotides adsorbed/conjugated to the surface of the carriers [17,18]. In 
this instance, decoupling the kinetic processes of carrier arrival to the cell surface and the ultimate 
response will allow for better understanding of the mechanism of action of various carriers, their 
transport in the tissues of interest [19] and ways to improve the therapeutic efficacy. Consequently, 
many studies have reported an increase in the therapeutic efficacy of a drug when coupled with a 
nano or micro material [20,21] or when particles alone have been introduced to cells to cause 
antitumor [22] or antibacterial activity [23]. Our model can be used to validate the numerous studies 
performed relating size dependent cellular uptake and biological effect of nano and micro-material 
in vitro. For instance, in a study [24] which reported a carrier size-dependent increase in cellular 
concentration of paclitaxel loaded PLGA particles, decoupling the effect of particle arrival from the 
reported biological effects could shed more lights on the mechanisms underlying the efficacy of the 
investigated carriers on the cellular level.  
The development of a wide range of drug delivery systems, spanning nano, micro and mesoscopic 
scales, has resulted in a powerful array of therapeutics. Considerable efforts have been invested in 
the characterisation of these advanced delivery vectors, however the difference in size between 
systems has numerous effects, limiting the ability to compare their performance. [25–30] Whilst the 
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pharmacology of many specific drug delivery vectors is well reported, there is little or no literature 
on comparative studies, which encompass various scales. Existing reports primarily focus on 
size[31,32] or shape[33,34] changes within a single drug delivery system. The pronounced surface 
to volume ratio scaling as size is reduced to the nanoscale affects the physical nature of the particles 
and their biological effects.[35] As an example, a larger size of the carrier can be linked to a better 
encapsulation capacity, higher weight of particle, faster sedimentation rate and larger total surface 
area of individual particles but collectively lower surface area per unit weight. On the other hand, 
smaller particles are more likely to aggregate and bind more efficiently to surfaces/receptors, when 
functionalized.[36–38]  
The above differences in the physical characteristics of the carriers pose difficulties in comparing 
the functional biologically/pharmacologically relevant behaviours across the systems, considering 
similar mass/volume concentration ranges.[39,40] In standard liquid-based cell culture systems, the 
number of particles associated with cells at any time is a function of the rate of delivery of drug 
vectors to the cells, the mode of vectors‟ interaction with the cell surface, and the rates of cellular 
uptake and loss by degradation or exocytosis. Therefore, the definition of dose for drug vectors in 
an in vitro system is more dynamic, more complicated, and less comparable across particulates than 
it is for soluble chemicals. Particulates diffuse, agglomerate and settle in cell culture media as a 
function of their individual properties, such as particle size, shape, surface charge and density; and 
environmental factors, such as media volume and viscosity. These factors also determine the rate of 
transport of drug vectors to cells in culture, thus providing a background for biased evaluation of 
biological responses. For example, Lison et. al. demonstrated differences in nominal and effective 
dose arising from silica particle concentration, media volume and height [39] and Limbach et. al. 
have presented experimental evidence that transport to cells of 25-50 nm and 250-500 nm cerium 
oxide particles is different, depending in the former case on diffusion and the latter case on 
gravitational settling.[32] This differential transport was shown to affect cellular uptake rates and 
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toxicity. In an insightful study Wittmaack showed that a unified description of particle-cell 
interaction can be obtained despite varying experimental factors, provided that the key determinant 
of cell response in known. This showed that for nanoparticles a universal response curve can be 
obtained when presented as a function of areal mass density of particles transported to cells.[41]    
 
In this study, we aim to provide a general framework for the benchmarking of drug vectors of 
differing materials across size scales, presenting a unified theory for dose-response for an arbitrary 
drug delivery vehicle. Our approach is based and validated on experimental data obtained using a 
model system of cationic polyethylene imine (PEI) based macromolecules (mol-PEI), and surface 
coated nano- and microparticles (NP-PEI and P-PEI) delivered to Human foreskin fibroblast cells 
(HFF-1). These delivery vehicles are chosen to span molecular to micro scales and in doing so they 
account for different modes of delivery to the cell with diffusion dominating molecular transport, 
diffusion and sedimentation dictating the nanoparticle motion and sedimentation alone being the 
dominant transport mechanism for the microparticles. As we have previously reported, since PEI 
has almost immediate biological effects directly related to its contact with the cell membrane, this 
molecule provides an ideal model for comparing behaviors of various drug vectors.[42,43] We 
stress that this is not a biology focused study from which we try to understand the cellular response; 
rather, it is a presentation and validation of a technique for comparing the performance of different 
scales of drug delivery systems. We show that the delivery kinetics of PEI to the cells is highly 
correlated with the dynamics of cell death and use the benchmarking analysis to obtain a hypothesis 
that the magnitude of the biological response to PEI is determined by the total number of PEI 
molecules delivered to the cells by surface attachment to the various delivery vectors. 
 
2. Methods 
Cell culture: Human foreskin fibroblast cells (HFF-1, ATCC® SCRC-1041™) were obtained from 
American type culture collection (ATCC, Manassas, Virginia, USA). The cells were cultured in 75 
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cm
2
 flasks in a humidified incubator at 37°C with 5% CO2 in Dulbecco's modified Eagle's medium 
(DMEM, ATCC) supplemented with 15% fetal bovine serum (FBS, Invitrogen, USA), 4 mM L-
glutamine, 1 mM sodium pyruvate and 1% penicillin (50 IU mL
-1
) /streptomycin (50 g mL-1).  
Delivery vectors: The tested systems included polyethylenimine (PEI, Mw 25,000, density 1.030 g 
mL
-1
, Sigma Aldrich, USA), PEI modified nanoparticles (NP-PEI) and PEI modified microparticles 
(µP-PEI). NP-PEI: PEI modified quantum dots (QD), were synthetized as previously described 
[42,44].  To obtain µP-PEI, spherical silica beads, (0.9 μm diameter and zeta potential -28.1mV) 
were obtained from Polysciences Inc. (USA). The beads were sonicated and washed 3-4 times in DI 
water (followed by centrifugation at 20,000g for 10 min). Further, the supernatant was removed and 
the microparticles were oxidized with 10% HNO3 in DI water for 30 min. Following centrifugation 
and three washes with isopropyl alcohol (IPA), PEI functionalization was performed using 1mL 
(1.030g) PEI dissolved in 5mL IPA and 250L DI water. Particles were treated with PEI/IPA/water 
solution at 35°C with 1300 rpm mixing for 2 h. The particles were washed five times with fresh IPA 
to remove any residual PEI molecules and re-suspended in the cell media immediately prior to 
dosing the cells.  
Particle characterisation: Both NP-PEI and µP-PEI systems were characterized for zeta potential 
and hydrodynamic diameter using a Zetasizer Nano ZS (Malvern Corp, Worcestershire, UK). For 
the analysis, NP-PEI and µP-PEI were suspended in phosphate buffer (PB, pH 7.4) at a 
concentration of 21 nM the results were recorded in triplicate. PEI-QD diameter was also assessed 
from scanning electron micrographs.  
Time-resolved microscopy, measurement of cell death: Cytotoxicity was quantified using DRAQ7 
staining, kindly provided by Biostatus Ltd (UK). Cells were seeded at a concentration of 70,000 
cells per well in Greiner Bio One Cellstar® tissue culture 6-well plate for 24 h.  The NP-PEI and 
P-PEI along with 3µM concentration of DRAQ7 was placed in 2mL of complete medium before 
being vortexed for 5 sec to ensure thorough mixing. The cells were washed twice in serum-free 
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medium and incubated with 2 mL of complete medium containing the dose and DRAQ7. High 
throughput, time-lapse based experiments were performed within 5-10 min of dosing using the In-
Cell Analyzer 2000 microscope (GE Healthcare, USA). Images were obtained once every hour for 
24 h of over 4,000 cells at each time point. Cells were imaged at 20x magnification in two channels: 
the DRAQ7 channel and the bright-field channel. If NP-PEI were involved in the assay, they were 
imaged with excitation and emission wavelengths of 350 and 568 nm respectively. At the end of the 
time-lapse experiment the cells were dosed with a very high dose (10 M) of NP-PEI in 2 mL 
media with 0.5 h exposure, which killed 100% of cells in each well. An additional set of images 
was then collected, from which a measure of the total number of cells in each well was obtained.  
Measurement of delivery vector accumulation: The time course of each delivery vector reaching the 
bottom of a cell culture well was measured using time-lapse microscopy. The wells of a flat base 6 
well-Olympus plate (no cells) were dosed with various concentrations of free mol-PEI, NP-PEI and 
P-PEI in triplicate. All were suspended in 2mL of DMEM plus 15% FBS. The wells had a 
diameter of 34.8 mm, which meant that when filled with 2 mL of media the height of the media is 
2.1mm. The ImageXpress High-Content Analyzer  (Molecular Devices, USA) obtained brightfield 
images using transmitted white light and also fluorescent images of the NP-PEI using their 
fluorescent channel (Ex/Em 350/568 nm) on the bottom surface of the well where cells would 
normally reside. The images were taken once every hour. The media was maintained at a constant 
temperature of 37°C. ImageJ 1.45 software (National Institutes of Health) was used to manually 
measure the mean pixel intensity, as pixel intensity can be assumed to be proportional to particle 
dose at a given time point. The inverse mean pixel intensity of 81 brightfield images of free PEI and 
P-PEI was used to quantify the amount of free PEI and P-PEI, as these are non-fluorescent and 
produced a dark area within the image. 
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3. Results 
3.1. Characterisation of delivery vectors 
Details relating to characterisation of delivery vector size and surface charge are presented in 
Figure 1 and summarised in Table 1. Coating of the vectors with the 25 kDa PEI produces a 
cationic surface layer of ~ 15-25 nm thickness with high positive charge ( value > +15 mV). The 
surface charge carried by the PEI is highly disruptive to cells, damaging the lipid membrane and 
causing rapid death.[43] This direct action of the PEI cargo results in a rapid cellular response and 
so the temporal dependence of the exposure-response characteristics is determined primarily by the 
physical processes of vector delivery rather than downstream biological mechanisms.[42] Thus this 
delivery vector/cargo system is well suited for the development of a generic protocol, focused on 
the relation of vector size to the delivered cargo dose. 
3.2. Exposure-response profiles 
We begin our presentation of the cell response profiles with the pharmacological standard of an 
end-point, exposure-response curve. Data is presented in Figure 2 on the % cell death after 24 
hours of exposure to the three drug vectors, across a range of concentrations. For each delivery 
system the assay delivers a full description of the concentration dependent cell response. However a 
common understanding of all three systems through the fundamental mechanisms that determine 
their cell interactions cannot be obtained directly. It is clear that there is a widely differing potency, 
dependent upon the vector size. Whilst this could be anticipated, it is difficult to gain any 
quantitative insight as the „delivered dose‟ is determined by counteracting effects - a reduced 
concentration of larger delivery vectors is linked to increased numbers of PEI cargo molecules per 
vector. Crucially, the measurements cannot report on any of the processes that drive the 
pharmacodynamics, for this is a single time-point assay. 
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To overcome these limitations we adopt an alternative approach, based on time-lapse imaging of the 
cells [42] to obtain time-mortality data.[45] This allows observation of the dynamics of cell 
response as the delivery vector concentration is increased. Results for all 3 vectors, at varying 
concentration, taken over a 24 hour exposure period are shown in Figure 3. When the cell response 
is viewed as a temporal process, the influence of the vector delivery becomes immediately apparent. 
The rapid delivery of the relatively heavy microparticles (P-PEI) through sedimentation produces 
a quick response with cell death rapidly increasing and then plateauing within a few hours, 
regardless of the exposure concentration. In contrast the lighter nanoparticle and molecule systems 
show slower and more complex dynamics, the form of which is dependent upon the delivery-vector 
concentration. This is as expected since the delivery in these cases is driven by both sedimentation 
and diffusion with the relative weighting of these processes dependent upon particle size and 
density.[46] The response profile for the P-PEI has a constant form with the % cell death scaling 
linearly with exposure concentration. This is indicative of a dose-response that is purely delivery 
dependent with the time to cell death determined by the sedimentation velocity and culture medium 
height and the maximum % of cells dying controlled by the available particle dose. In all cases there 
is a saturation in the cell mortality below 100% for lower exposure concentrations and we attribute 
this to depletion of the delivery vectors from the supply reservoir.[42,46]  
Close inspection of the time-mortality curves for NP-PEI and mol-PEI would seem to indicate 
anomalous results as the time response of the cells is similar whereas the diffusion/sedimentation 
dynamics of the nanoparticles and molecules should be orders of magnitude different. The response 
profile is determined by (1) the time dependent arrival of the PEI dose and (2) the susceptibility 
distribution of the cell population, i.e. the accumulated dose at a particular time point and the 
heterogeneity in the cells‟ response to this dose. Thus, to further investigate the results shown in 
Figure 3 we need to isolate these two factors. 
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3.3. Delivery vector accumulation dynamics 
To decouple the delivery of the PEI vectors from the cell response we assessed their arrival kinetics 
onto a culture well surface without the presence of cells. Measurement of the relative changes in 
delivery vector concentration follows from analysis of microscopy images of the well surface. The 
NP-PEI quantity is assessed by measurement of total nanoparticle fluorescence whereas the P-PEI 
and mol-PEI vectors are quantified from analysis of bright-field images. Example images, taken for 
each delivery vector after 24 hours of accumulation, are shown in Figure 4. The fact that the mol-
PEI can be directly imaged using optical microscopy indicates that there is substantial 
agglomeration occurring within the culture medium and that the delivery vector in this case is not 
molecular in scale at the point of interaction with cells.  
Using the diameter of the PEI agglomerates, measured from the microscopy images, we can 
estimate the mean number of molecules per agglomerate. The average diameter is 930 nm (N = 50) 
and they have a surface density of 5.2x10
7
 cm
-2
, thus the total number of agglomerates across the 
9.5 cm
2
 area of the culture well is 49.4x10
7
. Assuming that all of the PEI molecules are in an 
agglomerated form then we estimate a mean number per aggregate of 1.2x10
16
/49.4x10
7
 = 2.4x10
7
 
molecules (total molecule number calculated for 10 M concentration and 2 ml volume). This total 
number of molecules, Nmol is related to the overall agglomerate size, dagg: 
3
agg
mol
mol
d
N
d
 
  
 
 (1) 
where dmol is the mean spacing of molecules in the cluster. In this case, dmol = 3.2 nm, which 
corresponds closely to typical diameters for molecules of this weight (25 kDa),[47] indicating that 
the PEI has formed tightly packed agglomerates. The dramatically increased „effective size‟ of the 
PEI molecules caused by agglomeration explains the similarity in cellular response dynamics for 
mol-PEI and NP-PEI seen in Figure 3. The delivery rate of the approximately micron sized PEI 
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agglomerates is similar to the heavier but smaller quantum dots. An approximate estimate of the 
sedimentation velocity for the two delivery systems confirms that it is of the same order of 
magnitude for both (dNP = 15 nm, dPEI = 930 nm, NP = 5.8 g cm
-3
, PEI = 1.03 g cm
-3
).   
The full time course data is shown in Figure 5. In the case of the P-PEI, where the delivery in 
vitro is sedimentation dominated, the particle velocity is independent of particle concentration and 
all delivery vectors arrive at the surface within 5 hours. The lighter NP-PEI and mol-PEI systems 
display an extended characteristic in which the rate of signal increase drops off over time as the 
vector supply in the solution is reduced. To obtain a reliable metric of the vector accumulation 
dynamics we fit the data with the equation.[42] 
  0 1
ts t s e      (2) 
Where S is the measured signal and S0 the maximum signal due to all delivery vectors being present 
at the surface.  is a characteristic „accumulation time‟ that defines the time frame for particle 
arrival. It describes the dynamics of the system as described by the relative changes in S, as in all 
lifetime-based measures  is independent of the absolute scaling of S. Thus  can be obtained 
through secondary measures that are proportional to vector concentration (e.g. fluorescence or 
brightfield pixel intensity). The accumulation time effectively parameterises the delivery dynamics 
by quantifying the particle motion resulting from diffusion and sedimentation with a single metric. 
The equation is derived from a consideration of a closed system with a fixed supply reservoir from 
which particles are delivered to a surface.[42] The measured data plus modelled fits are shown in 
Figure 5. Whilst the fits lines do not accurately match the data for all vector concentrations, 
nonetheless Equation 2 does provides a realistic description of the curve profiles for all three 
delivery vector types and scales appropriately across the full range of concentrations.  
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The formulation and validation of a calibrated vector delivery equation provides a powerful tool 
with which we can move from exposure metrics to quantification of delivered dose. The measured 
signal, S in Equation 2 can be replaced by the vector number, N to which it is linearly correlated: 
  1 tN t CV e      (3) 
Where C is the exposure concentration of the vector and V the volume of the exposure medium (CV 
= No). Equation 3 can be used to transform time-mortality data into delivered dose-mortality 
curves using known values of C and V together with  values determined from the data fits in Figure 
5. The results of this transformation for the three delivery vector systems (data in Figure 3) are 
shown in Figure 6. The cell response is now related to the vector dose accumulated at the cell 
surface, thus different exposure concentrations (colour-labelled in Figure 6) produce a series of 
curves that lie on the same profile and extend to a maximum length determined by the concentration 
(maximum possible dose). This is as expected and a demonstration of Haber‟s law– the 
accumulated dose is a product of the concentration of the agent and the duration of exposure.[48] 
Whilst the form of the delivered dose-mortality curves is similar to the standard exposure-response 
data taken at t = 24 hours (Figure 2) they differ in one very important aspect: the delivered dose-
mortality curves are time independent. In using Equation 3 to remove the kinetics of vector delivery 
to the cell surface in vitro we have obtained response profiles that describe the innate biological 
susceptibility to the exposure agent. If the correct relationship between delivery vector size and PEI 
potency can now be obtained then transformation of this delivered dose into a determinant of 
biological effect (toxicity or mortality) will produce a unified, global response curve that describes 
the % cell death independent of the form of carrier by which the toxin is delivered. 
3.4. Investigating the controlling factor for cellular response 
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The dose-mortality curves shown in Figure 6 are different for the three delivery vehicle systems. 
However, in each case it is the same toxic agent, cationic PEI that is causing cell death, thus the 
differences must stem from the packing of the agent on each delivery vehicle. The data, therefore, 
describe a secondary factor related to the presentation of the PEI molecules to the cells rather than 
the primary cell-toxin interaction. However, the delivered dose-mortality curves do provide a means 
by which various hypotheses on the form of this primary interaction can be investigated. If we can 
correctly identify the mechanism of toxicity and find the mathematical relationship that links it to 
the delivered drug vehicle dose then we can transform the individual response curves for different 
delivery systems into a single, global curve of drug response, independent of the means by which 
the drug reaches the cell. 
The first step in this investigation addresses the fact that the PEI agglomerates when in molecular 
form. The concentration of the delivered mol-PEI used in Figure 6 must, therefore, be corrected to 
report the effective agglomerated vector concentration rather than that predicted under the 
assumption of a monodisperse molecular solution. This is simply done by dividing the delivered 
dose value by our estimate of the mean number of PEI molecules per agglomerate (N = 2.4x10
7
). 
The results of this transformation are shown in Figure 7A. The role of the delivery vector size now 
becomes very apparent as the mol-PEI and P-mol systems, which have near equal diameters, show 
nearly identical dose-mortality profiles. Even with agglomeration the concentration of mol-PEI 
remains higher than that of the P-mol (maximum concentration of 16,000 fM cf. 300 fM) and so 
the data extends over the full % range for cell death in this case. 
The data in Figure 7A shows that an equivalent cell response is produced by PEI molecules when 
they are attached to the surface of a micron scale particle and when they aggregate into a molecular 
cluster of the same dimensions. This observation leads to the hypothesis that it is the availability of 
PEI at the surface of the delivery vector that determines the level of toxicity. To test this hypothesis 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
16 
 
we calculated the mean number of surface PEI molecules per vector using the measured vector 
diameters (microparticle = 950 nm, molecular agglomerate = 930 nm, nanoparticle = 15 nm) and an 
assumed PEI spacing of 3.2 nm. The calculated values were then converted into a molar 
concentration by multiplying by the effective vector dose concentration (independent variable in 
Figure 7A). The result of this dose metric transform is shown in Figure 7B. A unified result is 
indeed obtained with all delivery vector types and exposure concentrations producing a dose-
mortality curve that sits on the same global profile. This confirms the hypothesis that it is the total 
number of PEI molecules presented to the cell on a delivery vector surface, which determines the 
level of cellular toxicity. The curve in Figure 7B is graphical evidence of the potential of this 
benchmarking approach for comparison of drug delivery vehicles, regardless of their material 
composition or size, and the extraction of the true therapeutic/toxic interaction of the drug/toxin 
with cells. 
 
 
4. Discussion 
Optimal drug delivery necessitates selective use of particular delivery vehicles, chosen from a wide 
range of candidate designs and materials dependent upon the nature of the drug and its specified 
target, and so techniques for benchmarking pharmacological performance across systems are 
essential. This poses a significant challenge in separating the multiple processes and mechanisms 
that determine a dose-response profile and which are dependent upon the delivery vector 
characteristics and the toxicity of its cargo. The time resolved analysis that we present provides a 
measurement based technique for separating these processes.  
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By implementing a simple, phenomenological, vector reservoir model we are able to accurately 
describe the arrival of delivery vectors at the cell surface, allowing us to transform a time-
dependence into a dose accumulation. This crucial step separates the processes of drug delivery and 
drug activity in vitro and avoids the complicated dynamics of particle motion in solution[40] by 
directly determining the resultant dose without need to consider the delivery process. Using this 
transformation of data from an exposure-response form to a delivered dose-response profile, 
comparisons can be made of the effectiveness of different drug delivery vectors, according to their 
presentation of the drug to cells rather than their efficiency of delivery. This allows an 
understanding of the influence of drug packaging by a carrier vector upon the response of a 
biological system. Indeed, when fully implemented the benchmarking procedure can provide a 
single, global drug response metric that identifies the determinant of drug potency and quantifies its 
influence according to the chosen carrier vector. 
The implementation of delivery vector benchmarking presented here has allowed us to compare the 
free delivery of a cationic molecule to carrier-based delivery using nano and microscale particles. 
The technique enables us to infer the presence of agglomeration of the free molecules from the 
time-resolved cellular response data and to identify the total number of molecules attached to the 
delivery vector surface as the primary factor determining cell death. The protocol can be 
implemented across a wide range of delivery vectors, regardless of morphology, scale and 
composition and is reliant only on the ability to perform time-resolved cellular response studies. 
Wider adoption of this approach would allow multiscale, cross-material comparisons of drug 
delivery vectors and optimisation of therapeutic effect based on analysis of the primary mechanism 
of drug action rather than secondary factors such as packing density on the delivery vehicle or the 
efficiency and speed of delivery.   
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Figure Captions: 
 
Table 1: Size and zeta potential parameters of the delivery vectors and PEI cargo. 
 
Figure 1: (A) Electron micrograph of NP-PEI; (B) NP-PEI size histogram based on electron 
micrograph; (C & D) Electron micrograph of bare µP and P-PEI respectively.   
 
Figure 2: Exposure-response curves after 24 hours of exposure for micro, nano and molecular 
delivery vectors. 
 
Figure 3: Time-mortality curves for (A) P-PEI; (B) NP-PEI and (C) mol-PEI treated HFF-1 cells. 
Arrows indicate direction of increasing exposure concentration; P-PEI: control (red), uncoated – 
31 fM (magenta), coated – 8 fM (blue), 15 fM (green), 31 fM (yellow), 76 fM (black), 153 fM 
(red), 306 fM (blue); NP-PEI: control (green), 1 nM (red), 2 nM (black), 3 nM (magenta), 4.5 nM 
(red), 5 nM (blue), 6 nM (black), 18 nM (blue), 45 nM (magenta); mol-PEI: control (red), 0.4 M 
(green),4 M (black),10 M (blue), 20 M (magenta), 40 M (green), 200 M (blue), 400 M 
(red). The error bars show the standard error in the mean (n=3). 
 
Figure 4: Bright field (mol-PEI and P-PEI) and fluorescence (NP-PEI) images of delivery vector 
accumulation on the culture well surface. Each image is of a 387x387 m area. 
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Figure 5: Time resolved arrival of delivery vectors onto the culture well surface for (A) P-PEI, (B) 
NP-PEI and (C) mol-PEI. The solid lines show a modelled fit using the indicated characteristic 
delivery time,  (see Equation 2). 
 
Figure 6: Dose-mortality curves calculated by transformation of data in Figure 3, using equation 2. 
Exposure concentrations used are; P-PEI: 15,31,76,153  fM; NP-PEI: 3,4.5,6,18 nM; mol-PEI: 
10,20,40,200 M. 
 
Figure 7: Biological response (% of cell death) as a function of: (A) effective vector dose 
concentration and (B) the solution concentration of the PEI molecules that are present at the surface 
of the delivery vectors. Legend: P-PEI (blue symbols), NP-PEI (red symbols) and mol-PEI (green 
symbols), original data shown in Figure 6. 
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Graphical Abstract 
Many of the key advances in Nanomedicine relate to the concept of delivery of a drug via a secondary 
carrier – a delivery vector. Here we present an experimental approach that allows quantitative comparison 
of delivery vectors across scales. This allows detailed analysis and discrimination of the relative roles of the 
carrier and the drug in determining cell response.    
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Table 1: Size and zeta potential parameters of the delivery vectors and PEI cargo. 
Delivery vector Size (nm) 
Bare particle (PEI coated form) 
Zeta-potential (mV) 
µP-PEI, microparticle 950 (1100) + 15.2 +/- 5.2 
NP-PEI, nanoparticle 15
a
 (34) + 18.6 +/- 5.7 
PEI, molecule 25 kDa weight  
a
 value reported in [44] 
